BiotechTube

GP40221 + ozempic

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacokinetics

Conditions

Pharmacokinetics, Safety Issues, Bioequivalence

Trial Timeline

Jun 30, 2023 → May 5, 2024

NCT ID
NCT06497049

About GP40221 + ozempic

GP40221 + ozempic is a phase 1 stage product being developed by GEROPHARM for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT06497049. Target conditions include Pharmacokinetics, Safety Issues, Bioequivalence.

What happened to similar drugs?

5 of 5 similar drugs in Pharmacokinetics were approved

Approved (5) Terminated (0) Active (0)
✅tolterodine + mirabegronAstellas PharmaApproved
✅mirabegronAstellas PharmaApproved
✅Prograf + Tacrolimus HexalNovartisApproved
✅Aripiprazole + Aripiprazole + desvenlafaxine succinate sustained releasePfizerApproved
✅Tamoxifen + Tamoxifen and Desvenlafaxine Succinate Sustained ReleasePfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06497049Phase 1Completed

Competing Products

20 competing products in Pharmacokinetics

See all competitors
ProductCompanyStageHype Score
DFD-29 (Minocycline) Fasting + DFD-29 (Minocycline) Fed + Solodyn (Minocycline) FastingDr. Reddy's LaboratoriesPhase 1
26
DRL_PG + Pegfilgrastim Form A + Pegfilgrastim Form BDr. Reddy's LaboratoriesPhase 1
22
GP30341 capsules 200 mg + Standard therapyGEROPHARMPre-clinical
16
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
19
Rinsulin NPH + Humulin NPHGEROPHARMPre-clinical
16
Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)YuhanPhase 1
29
DS-8500a + ItraconazoleDaiichi SankyoPhase 1
29
Milademetan + Itraconazole + PosaconazoleDaiichi SankyoPhase 1
29
Pexidartinib + ProbenecidDaiichi SankyoPhase 1
29
DS-8500a + RosuvastatinDaiichi SankyoPhase 1
29
DS-8500aDaiichi SankyoPhase 1
29
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
29
tolterodine + mirabegronAstellas PharmaApproved
43
ASP3652Astellas PharmaPhase 1
29
ASP015K ER + ASP015K IRAstellas PharmaPhase 1
29
YM178 modified release (OCAS) + YM178 immediate release (IR)Astellas PharmaPhase 1
29
Isavuconazole + dextromethorphanAstellas PharmaPhase 1
29
mirabegron + metoprololAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
zolbetuximab + oxaliplatin + leucovorin + fluorouracil + Pembrolizumab + folinic acid + nivolumab + DocetaxelAstellas PharmaPhase 2
39